‘It’s a vote for hope’: first gene therapy for muscular dystrophy nears approval, but will it work?
By Sara Reardon,
Nature
| 06. 02. 2023
The road to gene therapies for genetic disorders has been long — and expensive — but the field could soon get some good news. On 22 June, the US Food and Drug Administration will decide whether to grant a fast-track approval to the first gene therapy for Duchenne muscular dystrophy (DMD), a genetic disorder that affects around 1 in 3,500 boys. Children with DMD can’t make a protein called dystrophin, resulting in progressive muscle degeneration and death in their twenties due to heart or respiratory failure.
The therapy, known as SRP-9001, is made by Sarepta Therapeutics based in Cambridge, Massachusetts. It would be the 13th gene therapy that the FDA has approved since 2017, and the first to target a prevalent genetic disease in children. The accelerated approval would allow the drug to reach the market before large clinical trials have been completed, on the basis of evidence that the therapy allows boys to make an engineered form of dystrophin.
The decision date was delayed late in May after FDA officials and advisers raised concerns about the strength of Sarepta’s...
Related Articles
By Anumita Kaur [cites CGS’ Katie Hasson], The Washington Post | 03.25.2025
Genetic information company 23andMe has said that it is headed to bankruptcy court, raising questions for what happens to the DNA shared by millions of people with the company via saliva test kits.
Sunday’s announcement clears the way for a new...
By Peter Wehling, Tino Plümecke, and Isabelle Bartram
| 03.26.2025
This article was originally published as “Soziogenomik und polygene Scores” in issue 272 (February 2025) of the German-language journal Gen-ethischer Informationsdienst (GID); translated by the authors.
In mid-November 2024, the British organization Hope not Hate published its investigative research ‘Inside the Eugenics Revival’. In addition to documentating an active international “race research” network, the investigation also brought to light the existence of a US start-up that offers eugenic embryo selection. Heliospect Genomics aims to enable wealthy couples to...
By Frank Landymore, Futurism | 03.18.2025
You can only throw so much money at a problem.
This, more or less, is the line being taken by AI researchers in a recent survey. Asked whether "scaling up" current AI approaches could lead to achieving artificial general...
By Craig S. Smith, Forbes | 03.08.2025
One recent evening in Shenzhen, a group of software engineers gathered in a dimly lit co-working space, furiously typing as they monitored the performance of a new AI system. The air was electric, thick with the hum of servers and...